Compare Repligen Corporation Common Stock (RGEN) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Invesco S&P 500 High Div Low Volatility ETF trades at $49.81 (market cap $3.20B). The key difference: Repligen Corporation Common Stock is far larger — about 3.5× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Invesco S&P 500 High Div Low Volatility ETF for 126 Days on average.
| RGEN | SPHD | |
|---|---|---|
Market Cap | $11.14B | $3.20B |
Volume | 1,259,263 | 1,075,230 |
Sector | Health | — |
52-Week High | $194.57 | $53.55 |
52-Week Low | $102.87 | $46.96 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SPHD, the Invesco S&P 500 High Dividend Low Volatility ETF, trades at $49.29, up 0.1% on the day. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while the RSI suggests mild overbought conditions. The ETF focuses on high dividend yields and low volatility, attracting income-focused investors, though recent news highlights performance comparisons with peers like SCHD.
The outlook for SPHD hinges on its dividend strategy amid market volatility. Opportunities include steady income for retirees, but risks involve underperformance versus growth-focused ETFs and sensitivity to interest rate changes. Investors should weigh the trade-off between yield and total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
